Goichi Yoshimoto
Overview
Explore the profile of Goichi Yoshimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Taniguchi S, Utsumi S, Kochi Y, Taya Y, Mori Y, Semba Y, et al.
Int J Hematol
. 2022 Sep;
117(2):287-292.
PMID: 36136227
Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome...
12.
Sugio T, Baba S, Mori Y, Yoshimoto G, Kamesaki K, Takashima S, et al.
Int J Hematol
. 2022 Jun;
116(4):603-611.
PMID: 35701707
Relapsed and refractory aggressive lymphoma have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is effective in chemosensitive patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
13.
Moriyama S, Fukata M, Hieda M, Yokoyama T, Yoshimoto G, Kusaba H, et al.
Open Heart
. 2022 May;
9(1).
PMID: 35606045
Objective: Heart failure following allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a serious complication that requires early detection; however, the clinical implications of early-onset cancer therapy-related cardiac dysfunction (CTRCD) following...
14.
Yoshimoto G, Miyamoto T
Gan To Kagaku Ryoho
. 2022 May;
49(5):536-540.
PMID: 35578929
No abstract available.
15.
Mori Y, Harada T, Yoshimoto G, Shima T, Numata A, Jinnouchi F, et al.
Int J Hematol
. 2022 May;
116(2):258-265.
PMID: 35524024
Prophylactic use of letermovir (LMV) markedly reduces the incidence of early clinically significant cytomegalovirus (csCMV) infection within the first 100 days after allogeneic hematopoietic cell transplantation (allo-HCT), which improves transplant...
16.
Zhang M, Tajima S, Suetsugu K, Hirota T, Tsuchiya Y, Yamauchi T, et al.
Ther Drug Monit
. 2022 Feb;
44(4):592-596.
PMID: 35149666
Background: Gilteritinib, a novel oral tyrosine kinase inhibitor, is used to treat acute myeloid leukemia (AML) with FMS-like tyrosine kinase-3 (FLT3) mutations. Therapeutic drug monitoring (TDM) of gilteritinib is important...
17.
Jinnouchi F, Mori Y, Yoshimoto G, Yamauchi T, Nunomura T, Yurino A, et al.
Int J Hematol
. 2021 Oct;
115(1):96-106.
PMID: 34652633
Post-transplant cytomegalovirus (CMV) disease can be almost completely avoided by current infection control procedures. However, CMV reactivation occurs in more than half of patients, and some patients can develop clinically...
18.
Yoshimoto G
Rinsho Ketsueki
. 2021 Sep;
62(8):967-977.
PMID: 34497237
The etiology and pathogenesis of acute myeloid leukemia (AML) have been elucidated at chromosomal and genetic levels. The classification and prognosis for its treatment has clearly involved specific chromosomal aberrations...
19.
Yoshimoto G, Mori Y, Kato K, Odawara J, Kuriyama T, Ueno T, et al.
Leuk Lymphoma
. 2021 Jun;
62(12):2939-2948.
PMID: 34159882
We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) ( = 20)...
20.
Harada T, Iwasaki H, Muta T, Urata S, Sakamoto A, Kohno K, et al.
Br J Haematol
. 2021 Apr;
194(1):101-110.
PMID: 33822354
Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased. However, whether ts/bDMARDs...